Skip Navigation

Lynch Syndrome

printer friendly version


A phase Ib biomarker trial of naproxen in patients at risk for DNA mismatch repair deficient colorectal cancer

 

Study Description

Lynch syndrome is an inherited disorder that increases the risk of certain types of cancer, particularly cancers of the colon (large intestine) and rectum, which are collectively referred to as colorectal cancer.

This is a biomarker study being conducted to determine if taking naproxen can reduce the risk of colorectal cancer in people with Lynch syndrome. Naproxen is a nonsteroidal antiinflammatory drug (NSAID) that has been marketed under the brand name Aleve®.

Subject Eligibility

Study Design

About 60 eligible subjects with Lynch syndrome from multiple centers will be randomized to receive either 220 mg naproxen, 440 mg naproxen, or placebo for up to 6 months. 

Requirements

Over the 6-month study period, be willing to:

Primary Investigator: Elena Stoffel, MD, MPH

Co-investigator: D. Kim Turgeon, MD

Study Coordinator: Erika Koeppe, e-mail: eskoeppe@med.umich.edu phone: (734) 998-1274